VolitionRx Limited (NYSE American: VNRX) has highlighted a growing body of clinical and scientific evidence supporting its Nu.Q NETs assay as a biomarker for sepsis and other diseases associated with NETosis. The company released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, who discusses the clinical utility of the test.
Multiple studies have demonstrated that VolitionRx's Nu.Q H3.1 test can distinguish sepsis from non-infectious inflammation, correlate with disease severity, and provide strong prognostic value for outcomes including organ failure and mortality. According to the company, most of the supporting research has been peer-reviewed and published, with experts noting the consistency of findings across multiple countries and patient populations.
VolitionRx believes its low-cost nucleosome quantification technology could help personalize patient care by identifying elevated H3.1 nucleosome levels as a treatable trait in sepsis management and informing future therapeutic strategies. The company is focused on advancing the science of epigenetics and developing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
For more information, visit the company's website at https://volition.com/. The full press release is available at https://ibn.fm/2IH3m.
VolitionRx is a multi-national company with research and development activities centered in Belgium, an innovation laboratory and office in the U.S., and an office in London. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
